{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:04:04Z","timestamp":1787169844332,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.ejim.2018.01.026","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T18:45:44Z","timestamp":1517510744000},"page":"78-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Factors reducing omalizumab response in severe asthma"],"prefix":"10.1016","volume":"52","author":[{"given":"B.","family":"Sposato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Scalese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Milanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Masieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cavaliere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Latorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Scichilone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Matucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vultaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cresti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Santus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Perrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.L.","family":"Paggiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2018.01.026_bb0005","author":"Global Initiative for Asthma"},{"issue":"24","key":"10.1016\/j.ejim.2018.01.026_bb0010","doi-asserted-by":"crossref","first-page":"9975","DOI":"10.1074\/jbc.M117.776476","article-title":"Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab","volume":"292","author":"Davies","year":"2017","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.ejim.2018.01.026_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2017.02.002","article-title":"\"Real-life\" effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis","volume":"5","author":"Alhossan","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.ejim.2018.01.026_bb0020","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pupt.2017.03.004","article-title":"Xolair Italian study group. Can the response to Omalizumab be influenced by treatment duration? A real-life study","volume":"44","author":"Sposato","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.ejim.2018.01.026_bb0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pupt.2014.09.007","article-title":"Xolair Italian study group. Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy","volume":"31","author":"Novelli","year":"2015","journal-title":"Pulm Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.ejim.2018.01.026_bb0030","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/imj.13166","article-title":"Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry","volume":"46","author":"Gibson","year":"2016","journal-title":"Intern Med J"},{"key":"10.1016\/j.ejim.2018.01.026_bb0035","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.rmed.2016.09.005","article-title":"Effects of omalizumab in severe asthmatics across ages: a real life Italian experience","volume":"119","author":"Sposato","year":"2016","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.ejim.2018.01.026_bb0040","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"issue":"10","key":"10.1016\/j.ejim.2018.01.026_bb0045","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1185\/030079907X226258","article-title":"Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis","volume":"23","author":"Busse","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"10.1016\/j.ejim.2018.01.026_bb0050","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.ejim.2018.01.026_bb0055","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3109\/02770903.2011.648296","article-title":"A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma","volume":"49","author":"Bardelas","year":"2012","journal-title":"J Asthma"},{"issue":"1","key":"10.1016\/j.ejim.2018.01.026_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2016.08.054","article-title":"A randomized multicenter study evaluating Xolair persistence of response after long-term therapy","volume":"140","author":"Ledford","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"17","key":"10.1016\/j.ejim.2018.01.026_bb0065","article-title":"After asthma: redefining airways diseases","volume":"S0140-6736","author":"Pavord","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2018.01.026_bb0070","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.2147\/CIA.S50496","article-title":"Effect of aging on airway remodeling and muscarinic receptors in a murine acute asthma model","volume":"8","author":"Kang","year":"2013","journal-title":"Clin Interv Aging"},{"issue":"9","key":"10.1016\/j.ejim.2018.01.026_bb0075","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3109\/02770903.2016.1167903","article-title":"CT-assessed large airway involvement and lung function decline in eosinophilic asthma: the association between induced sputum eosinophil differential counts and airway remodeling","volume":"53","author":"Inoue","year":"2016","journal-title":"J Asthma"},{"issue":"5","key":"10.1016\/j.ejim.2018.01.026_bb0080","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.anai.2014.08.002","article-title":"Pathophysiological characteristics of asthma in the elderly: a comprehensive study","volume":"113","author":"Inoue","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.ejim.2018.01.026_bb0085","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/resp.12079","article-title":"Relationship between airway neutrophilia and ageing in asthmatics and non-asthmatics","volume":"18","author":"Brooks","year":"2013","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.ejim.2018.01.026_bb0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/17476348.2017.1268919","article-title":"Neutrophilic inflammation in asthma: mechanisms and therapeutic considerations","volume":"11","author":"Chang","year":"2017","journal-title":"Expert Rev Respir Med"},{"issue":"5","key":"10.1016\/j.ejim.2018.01.026_bb0095","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/thx.2009.126722","article-title":"Effects of steroid therapy on inflammatory cell subtypes in asthma","volume":"65","author":"Cowan","year":"2010","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.ejim.2018.01.026_bb0100","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3109\/02770903.2014.975357","article-title":"Characteristics of eosinophilic and non-eosinophilic asthma during treatment with inhaled corticosteroids","volume":"52","author":"Furukawa","year":"2015","journal-title":"J Asthma"},{"issue":"3","key":"10.1016\/j.ejim.2018.01.026_bb0105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/1753465816632638","article-title":"Novel approaches to the management of noneosinophilic asthma","volume":"10","author":"Thomson","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.ejim.2018.01.026_bb0110","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/692546","article-title":"The impact of immunosenescence on pulmonary disease","volume":"2015","author":"Murray","year":"2015","journal-title":"Mediat Inflamm"},{"issue":"1","key":"10.1016\/j.ejim.2018.01.026_bb0115","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.rmed.2011.08.013","article-title":"Clinical characteristics and possible phenotypes of an adult severe asthma population","volume":"106","author":"de Carvalho-Pinto","year":"2012","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.ejim.2018.01.026_bb0120","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jaci.2010.08.011","article-title":"Age-related changes in immune function: effect on airway inflammation","volume":"126","author":"Busse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.ejim.2018.01.026_bb0125","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1183\/09031936.00139810","article-title":"Airway inflammation is augmented by obesity and fatty acids in asthma","volume":"38","author":"Scott","year":"2011","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.ejim.2018.01.026_bb0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11882-017-0719-9","article-title":"Role of obesity in asthma: mechanisms and management strategies","volume":"17","author":"Scott","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"issue":"9","key":"10.1016\/j.ejim.2018.01.026_bb0135","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3109\/02770903.2013.831871","article-title":"Sleep duration, asthma and obesity","volume":"50","author":"Teodorescu","year":"2013","journal-title":"J Asthma"},{"issue":"3","key":"10.1016\/j.ejim.2018.01.026_bb0140","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1183\/09031936.06.00077205","article-title":"Influence of body mass index on the response to asthma controller agents","volume":"27","author":"Peters-Golden","year":"2006","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.ejim.2018.01.026_bb0145","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1016\/j.rmed.2007.06.031","article-title":"Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma","volume":"101","author":"Boulet","year":"2007","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.ejim.2018.01.026_bb0150","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3109\/02770900903338494","article-title":"Body mass index and response to asthma therapy: fluticasone propionate\/salmeterol versus montelukast","volume":"47","author":"Camargo","year":"2010","journal-title":"J Asthma"},{"issue":"2","key":"10.1016\/j.ejim.2018.01.026_bb0155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000335926","article-title":"Airway hyperresponsiveness is negatively associated with obesity or overweight status in patients with asthma","volume":"159","author":"Kwon","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"issue":"3","key":"10.1016\/j.ejim.2018.01.026_bb0160","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1152\/japplphysiol.00749.2009","article-title":"Obesity, airway hyperresponsiveness and inflammation","volume":"108","author":"Shore","year":"2010","journal-title":"J Appl Physiol"},{"issue":"9","key":"10.1016\/j.ejim.2018.01.026_bb0165","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/ijo.2008.103","article-title":"Body composition and pulmonary function in the elderly: a 7-year longitudinal study","volume":"32","author":"Rossi","year":"2008","journal-title":"Int J Obes"},{"issue":"4","key":"10.1016\/j.ejim.2018.01.026_bb0170","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.anai.2012.07.017","article-title":"Association between obesity and asthma in the elderly population: potential roles of abdominal subcutaneous adiposity and sarcopenia","volume":"109","author":"Song","year":"2012","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.ejim.2018.01.026_bb0175","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2500\/aap.2011.32.3407","article-title":"Association between subcutaneous abdominal fat and airway hyperresponsiveness","volume":"32","author":"Kim","year":"2011","journal-title":"Allergy Asthma Proc"},{"issue":"5","key":"10.1016\/j.ejim.2018.01.026_bb0180","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jaci.2008.03.004","article-title":"Obesity and asthma: possible mechanisms","volume":"121","author":"Shore","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.ejim.2018.01.026_bb0185","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/j.1398-9995.2012.02855.x","article-title":"Obesity in asthma: more neutrophilic inflammation as a possible explanation for a reduced treatment response","volume":"67","author":"Telenga","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.ejim.2018.01.026_bb0190","article-title":"Eosinophilic and non-eosinophilic asthma","author":"Carr","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.ejim.2018.01.026_bb0195","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.jaci.2009.01.040","article-title":"Therapy and Health Economics Group of the European Community Respiratory Health Survey. Body mass index, weight gain, and other determinants of lung function decline in adult asthma","volume":"123","author":"Marcon","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.ejim.2018.01.026_bb0200","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.rmed.2007.12.022","article-title":"Changes in obesity status and lung function decline in a general population sample","volume":"102","author":"Pistelli","year":"2008","journal-title":"Respir Med"},{"issue":"7","key":"10.1016\/j.ejim.2018.01.026_bb0205","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/resp.12355","article-title":"Asthma and respiratory physiology: putting lung function into perspective","volume":"19","author":"Sferrazza Papa","year":"2014","journal-title":"Respirology"},{"issue":"6","key":"10.1016\/j.ejim.2018.01.026_bb0210","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/00325481.2016.1204211","article-title":"Obesity-related asthma in adults","volume":"128","author":"Bhatt","year":"2016","journal-title":"Postgrad Med"},{"issue":"3","key":"10.1016\/j.ejim.2018.01.026_bb0215","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1586\/ers.12.22","article-title":"The treatment of asthma in obesity","volume":"6","author":"Dixon","year":"2012","journal-title":"Expert Rev Respir Med"},{"issue":"4","key":"10.1016\/j.ejim.2018.01.026_bb0220","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/resp.13026","article-title":"Co-morbidities in severe asthma: clinical impact and management","volume":"22","author":"Porsbjerg","year":"2017","journal-title":"Respirology"},{"issue":"5","key":"10.1016\/j.ejim.2018.01.026_bb0225","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/13993003.00779-2015","article-title":"U-BIOPRED study group. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort","volume":"46","author":"Shaw","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2018.01.026_bb0230","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/607192","article-title":"Body mass index and comorbidities in adult severe asthmatics","volume":"2014","author":"Bruno","year":"2014","journal-title":"Biomed Res Int"},{"issue":"3","key":"10.1016\/j.ejim.2018.01.026_bb0235","doi-asserted-by":"crossref","first-page":"282","DOI":"10.4103\/0022-3859.138754","article-title":"Prevalence of gastro-esophageal reflux disease in patients with difficult to control asthma and effect of proton pump inhibitor therapy on asthma symptoms, reflux symptoms, pulmonary function and requirement for asthma medications","volume":"60","author":"Sandur","year":"2014","journal-title":"J Postgrad Med"},{"issue":"3","key":"10.1016\/j.ejim.2018.01.026_bb0240","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2500\/ajra.2015.29.4178","article-title":"Management of chronic rhinosinusitis with nasal polyps and coexisting asthma: a systematic review","volume":"29","author":"Rix","year":"2015","journal-title":"Am J Rhinol Allergy"},{"issue":"4","key":"10.1016\/j.ejim.2018.01.026_bb0245","article-title":"Association of chronic rhinosinusitis with nasal polyps and asthma: clinical and radiological features, allergy and inflammation markers","volume":"44","author":"Staik\u00fcniene","year":"2008","journal-title":"Med Kaunas"},{"issue":"7","key":"10.1016\/j.ejim.2018.01.026_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127228","article-title":"Airway inflammation in chronic rhinosinusitis with nasal polyps and asthma: the united airways concept further supported","volume":"10","author":"H\u00e5kansson","year":"2015","journal-title":"PLoSOne"},{"issue":"1","key":"10.1016\/j.ejim.2018.01.026_bb0255","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chest.2016.09.035","article-title":"Omalizumab treatment response in a population with severe allergic asthma and overlapping COPD","volume":"151","author":"Maltby","year":"2017","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ejim.2018.01.026_bb0260","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1183\/09031936.00099513","article-title":"Can overweight\/obesity and smoking have combined effects on bronchial hyperresponsiveness","volume":"43","author":"Sposato","year":"2014","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.ejim.2018.01.026_bb0265","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/j.ejim.2011.05.009","article-title":"Monosensitization and polysensitization in allergic rhinitis","volume":"22","author":"Ciprandi","year":"2011","journal-title":"Eur J Intern Med"},{"issue":"3","key":"10.1016\/j.ejim.2018.01.026_bb0270","article-title":"Respiratory allergens from furred mammals: environmental and occupational exposure","volume":"4","author":"Zahradnik","year":"2017","journal-title":"Vet Sci"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620518300268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620518300268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T20:11:40Z","timestamp":1538597500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620518300268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":54,"alternative-id":["S0953620518300268"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2018.01.026","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors reducing omalizumab response in severe asthma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2018.01.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}